In multiple myeloma (MM), ATR inhibition combined with MEK1/2 inhibitors, such as AZD6738 (21), triggered dual STAT3 dephosphorylation, leading to downregulation of survival proteins (c-Myc, BCL-XL) and increased MM cell death. Here, ATR is linked to Miyoshi myopathy.